Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$322.83 +1.4%	$286.24	$205.87 ▼ $326.03	$42.09B	0.22	859,177 shs	2.05 million shs
BIIB Biogen	$126.08 -0.7%	$125.68	$110.04 ▼ $238.00	$18.47B	0.14	1.43 million shs	1.10 million shs
BMRN BioMarin Pharmaceutical	$55.17 +2.0%	$58.39	$52.93 ▼ $94.85	$10.58B	0.19	1.72 million shs	3.33 million shs
INCY Incyte	$68.37 -3.4%	$64.49	$53.56 ▼ $83.95	$13.23B	0.67	1.98 million shs	3.50 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+4.24%	+5.99%	+19.56%	+32.85%
BIIB Biogen	0.00%	-0.76%	-3.84%	-7.86%	-45.61%
BMRN BioMarin Pharmaceutical	0.00%	+0.31%	-4.86%	-21.96%	-32.99%
INCY Incyte	0.00%	-0.13%	+4.78%	+12.91%	+12.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.2539 of 5 stars	2.4	4.0	4.3	3.9	2.5	0.6
BIIB Biogen	4.9519 of 5 stars	4.2	5.0	3.7	3.3	1.7	2.5
BMRN BioMarin Pharmaceutical	4.9475 of 5 stars	3.4	3.0	3.3	3.3	2.5	4.4
INCY Incyte	4.4209 of 5 stars	2.1	3.0	3.1	3.0	2.5	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.79	Moderate Buy	$337.91	4.67% Upside
BIIB Biogen	2.38	Hold	$188.48	49.49% Upside
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$93.45	69.39% Upside
INCY Incyte	2.22	Hold	$74.53	9.01% Upside

Current Analyst Ratings Breakdown

Latest BMRN, ALNY, BIIB, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/26/2025	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$187.00
6/25/2025	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$205.00 ➝ $213.00
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/23/2025	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Perform ➝ Sector Perform	$67.00
6/16/2025	INCY Incyte	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$75.00 ➝ $107.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/3/2025	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.72	N/A	N/A	$0.52 per share	620.83
BIIB Biogen	$9.68B	1.91	$23.09 per share	5.46	$114.71 per share	1.10
BMRN BioMarin Pharmaceutical	$2.85B	3.71	$3.25 per share	17.00	$29.69 per share	1.86
INCY Incyte	$4.24B	3.12	$0.55 per share	123.50	$17.90 per share	3.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	362.73	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BIIB Biogen	$1.63B	$10.13	12.45	7.64	1.00	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$426.86M	$2.69	20.51	12.65	0.76	17.76%	11.34%	8.95%	8/4/2025 (Estimated)
INCY Incyte	$32.62M	$0.32	213.66	10.45	0.58	0.48%	2.77%	1.77%	7/29/2025 (Estimated)

Latest BMRN, ALNY, BIIB, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/29/2025	Q1 2025	INCY Incyte	$1.01	$1.16	+$0.15	$0.80	$996.17 million	$1.05 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BIIB Biogen	0.27	1.44	1.01
BMRN BioMarin Pharmaceutical	0.10	5.52	3.49
INCY Incyte	0.01	2.04	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
BMRN BioMarin Pharmaceutical	98.71%
INCY Incyte	96.97%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
BIIB Biogen	0.18%
BMRN BioMarin Pharmaceutical	0.85%
INCY Incyte	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.82 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
BMRN BioMarin Pharmaceutical	3,040	191.78 million	190.15 million	Optionable
INCY Incyte	2,617	193.57 million	159.12 million	Optionable

BMRN, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

Illinois Municipal Retirement Fund Reduces Holdings in Incyte Corporation (NASDAQ:INCY)

June 28 at 5:17 AM | marketbeat.com

Diversified Trust Co Sells 6,555 Shares of Incyte Corporation (NASDAQ:INCY)

June 28 at 4:56 AM | marketbeat.com

Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?

June 27 at 10:37 PM | investors.com